Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults
Sponsor: Scott Silveira • ClinicalTrials.gov ID: NCT07144527
Recruiting for Similar Conditions?
Sponsors are looking for patients like you. See if you qualify for compensated research studies.
Check Eligibility →Description
This is a randomized, double-blind, placebo-controlled, two-arm crossover clinical trial evaluating the effects of nicotinamide mononucleotide (NMN) combined with trimethylglycine (TMG) supplementation, compared to NMN alone. The study will assess safety and efficacy in improving exercise tolerance and modulating biomarkers of aging in healthy older adults. The primary outcome is cycle ergometry constant work rate (CWR) exercise tolerance, measured as time to fatigue. Secondary outcomes include changes in peak oxygen consumption (VO₂peak), critical power, anaerobic work capacity, lactate threshold, and NAD⁺ metabolite levels. The supplements have been used in prior exploratory studies and real-world applications, which have helped inform the design of this current trial.
Interventions
-
NMN and TMG (Euexia)
(Dietary supplement)
Formulation containing NMN and TMG.
-
Nicotinamide Mononucleotide (NMN)
(Dietary supplement)
Conventional NMN supplement.
-
Placebo
(Dietary supplement)
Organoleptically matched inert control.
Eligibility criteria
Conditions
Locations
- Medical Office of Dr. Robert Huizenga MD — Beverly Hills, California, United States
Partner with Nurenyx
Showcase your study to thousands of motivated patients matching your criteria.
Learn MoreOfficial Source
Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
View Official Record